62 results
8-K
EX-99.1
VANI
Vivani Medical Inc
5 Mar 24
Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants
4:21pm
investigation of the safety, tolerability, and full pharmacokinetic profile of NPM-119 in patients with type 2 diabetes. Vivani is also preparing to submit
8-K
EX-10.2
zkr164gx n6y6arssyj
5 Mar 24
Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants
4:21pm
8-K
EX-10.1
u9lrn5a65
5 Mar 24
Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants
4:21pm
8-K
EX-99.1
6q0u8wb
28 Feb 24
Regulation FD Disclosure
8:30am
8-K
EX-99.2
qdmsct3qccdtp9sw
14 Nov 23
Results of Operations and Financial Condition
6:06am
8-K
EX-3.2
9fl80lw
10 Jul 23
Material Modifications to Rights of Security Holders
4:04pm
8-K
EX-99.2
46tqcempmmjael
15 May 23
Results of Operations and Financial Condition
6:49am
DEFR14A
eldbif
1 May 23
Revised proxy
4:49pm
8-K
EX-10.1
hlm1tu0g981fmoxeg
28 Nov 22
Entry into a Material Definitive Agreement
5:29pm
8-K
EX-99.1
e8cr mp4ujw
14 Nov 22
Vivani Medical Reports Third Quarter 2022 Results and Provides Business Updates
4:14pm